[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Antithrombotische Therapie bei akutem Koronarsyndrom und Vorhofflimmern.
Acute Coronary Syndrome
/ drug therapy
Acute Disease
Aspirin
/ adverse effects
Atrial Fibrillation
/ drug therapy
Clopidogrel
/ adverse effects
Combined Modality Therapy
Cyclophosphamide
/ adverse effects
Dabigatran
/ adverse effects
Drug Therapy, Combination
Fibrinolytic Agents
/ adverse effects
Hemorrhage
/ chemically induced
Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
/ adverse effects
Pyrazoles
/ adverse effects
Pyridones
/ adverse effects
Randomized Controlled Trials as Topic
Risk Factors
Rivaroxaban
/ adverse effects
Stents
Stroke
/ prevention & control
Vitamin K
/ antagonists & inhibitors
Journal
Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
2
2
2021
Statut:
ppublish
Résumé
The number of patients with atrial fibrillation (AF) is increasing due to the aging of the population. In addition, the number of patients with AF and an indication for oral anticoagulation (OAC) for the prevention of strokes increases, who are in need for a dual antiplatelet therapy (DAPT) with acetyl salicylic acid (ASA) plus a P2Y
Substances chimiques
Fibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Pyrazoles
0
Pyridones
0
Vitamin K
12001-79-5
apixaban
3Z9Y7UWC1J
Cyclophosphamide
8N3DW7272P
Rivaroxaban
9NDF7JZ4M3
Clopidogrel
A74586SNO7
Dabigatran
I0VM4M70GC
Aspirin
R16CO5Y76E
Types de publication
Comparative Study
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
978-986Informations de copyright
© Georg Thieme Verlag KG Stuttgart · New York.
Déclaration de conflit d'intérêts
Der Autor erklärt während der letzten 3 Jahre Vortrags- und Beraterhonorare von ff. Unternehmen erhalten zu haben: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DaiichiSankyo, Pfizer.